Association Between Eight Autoimmune Diseases and Thyroid Cancer: A Nationwide Cohort Study
Thyroid® · 2024
DOI: 10.1089/thy.2023.0353 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Thyroid®, 2024. Verfasst von Sung Keun Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Thyroiditis, Autoimmune, Vitiligo, Autoimmune Diseases, Hashimoto Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
It has often been reported that thyroid-specific autoimmune diseases (ADs), such as Hashimoto's thyroiditis and Graves' disease, could increase the risk of thyroid cancer, but the association between other ADs beyond thyroid and thyroid cancer has not been well investigated. This study aimed to examine the risk of thyroid cancer in patients with eight ADs compared with those without ADs.
Methods
This nationwide retrospective matched cohort study was conducted to investigate the relationship of eight ADs (Hashimoto's thyroiditis, Graves' disease, type 1 diabetes mellitus, Sjogren's disease, inflammatory bowel disease [IBD], vitiligo, systemic lupus erythematosus, and rheumatoid arthritis [RA]) with the risk of incident thyroid cancer using the National Health Insurance Service-National Sample Cohort. The Cox-proportional hazard model was used to estimate the adjusted hazard ratio (HR) and confidence intervals (CI) for thyroid cancer in relation to each of AD compared with control group without AD.
Results
During the average follow-up of 9.49 years, 138 thyroid cancer cases were newly developed in control group and 268 cases were occurred in group with 8 ADs. For all of study participants, the risk of thyroid cancer was significantly increased in patients with Hashimoto's thyroiditis (HR = 2.10 [1.57–2.81]), Graves' disease (HR = 2.67 [1.99–3.62]), IBD (HR = 2.06 [1.50–2.83]), vitiligo (HR = 1.71 [1.13–2.59]), RA (HR = 1.76 [1.07–2.90]), and total of 8 ADs (HR = 1.97 [1.60–2.42]) compared with control group without ADs. When ADs were divided into three types, thyroid-specific ADs (HR = 2.37 [1.85–3.03]) showed the strongest and significant association with thyroid cancer, followed by local ADs (HR = 1.83 [1.41–2.38]), and systemic ADs (HR = 1.77 [1.14–2.74]).
Conclusions
Specific ADs—especially for thyroid-specific AD, vitiligo, IBD, and RA—were associated with increased risk for thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.
- Department of Occupational and Environment Medicine, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Informatization Department, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea.
- Center for Thyroid Cancer, National Cancer Center, Goyang, Republic of Korea.
- Department of Preventive Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea.
- Department of Preventive Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
ORCID-Profile: Jae-Hong Ryoo, Ju Young Jung, Yuh-Seog Jung
Zitieren
APA
Park, S. K., Ryoo, J. H., Kim, M. H., Jung, J. Y., Jung, Y. S., Kim, K. N., Shin, S., & Oh, C. M. (2024). Association Between Eight Autoimmune Diseases and Thyroid Cancer: A Nationwide Cohort Study. Thyroid®. https://doi.org/10.1089/thy.2023.0353
Vancouver
Park SK, Ryoo JH, Kim MH, Jung JY, Jung YS, Kim KN, et al. Association Between Eight Autoimmune Diseases and Thyroid Cancer: A Nationwide Cohort Study. Thyroid®. 2024. doi:10.1089/thy.2023.0353
BibTeX
@article{Park2024,
author = {Park, Sung Keun and Ryoo, Jae-Hong and Kim, Min-Ho and Jung, Ju Young and Jung, Yuh-Seog and Kim, Kyoung-Nam and Shin, Soonsu and Oh, Chang-Mo},
title = {Association Between Eight Autoimmune Diseases and Thyroid Cancer: A Nationwide Cohort Study},
journal = {Thyroid®},
year = {2024},
doi = {10.1089/thy.2023.0353}
}
EUVIMED